Capricor Therapeutics announced the scale-up to expand manufacturing capacity of CAP-1002 to its new state-of-the-art manufacturing facility, intended for commercial use, subject to regulatory approval, located in San Diego. Furthermore, the Company announced that Cohort B of its HOPE-3, Phase 3 clinical study is enrolling rapidly and is expected to complete full enrollment (n=44) in the second quarter of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.3 USD | -2.21% | -3.11% | +8.38% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.38% | 167M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- CAPR Stock
- News Capricor Therapeutics, Inc.
- Capricor Therapeutics Announces Manufacturing Scale-Up of Cap-1002 Production At New San Diego Facility as It Continues Plans Toward Commercialization